abstract |
The present invention relates to the use of acetyl L-carnitine, or a pharmaceutically acceptable salt thereof, for the prevention of theadverse effects,such as steoporosis, weight gain and edema, due to the use ofPPAR-gamma agonists selected from the group consisting of spirolaxine or a glitazonederivative selected fromthe group consisting ofroglitazone, pioglitazone androsiglitazone. |